About Us

Our Team

  • Chief Investment Officer at Versa Capital Management, LLC
  • Over 25 years experience in Private Equity and Investment
  • J.D. from Stanford Law School (with distinction, law review, Order of the Coif)

Paul Halpern, J.D.

Founder, CEO and Managing Member

  • Scientific Founder of Immunome (NASDAQ:IMNM)
  • Joseph and Ray Gordon Chair in Clinical Oncology and Research at the Lankenau Medical Center in Wynnewood, PA
  • Yale M.D., Ph.D., with post-grad medical training at Dana Farber/Partners Cancer Care and the Whitehead Institute

Scott Dessain, M.D., Ph.D.

Founder and Chief Scientific Officer

  • Managed internal antibody discovery for Immunome; expertise in drug development and portfolio management
  • Developed assets for and contributed to strategic collaborations valued in excess of $3B
  • Duke Ph.D. with Presidential postdoc fellowship at Novartis

Pavel Nikitin, Ph.D.

Chief Development Officer

  • Onne Ganel has spent two decades in the healthcare technology field
  • Led acquisitions in excess of $500m in total value on behalf of Fortune 500 companies, and commercializing technologies across the healthcare spectrum

Onne Ganel, MBA

Business Development

  • Decorated Marine; expertise in strategic planning and project management
  • B.S. in neuroscience and philosophy from Vanderbilt University

Thomas Halpern, Capt USMC

Chief Operating Officer

  • Immunologist with over 18 years of experience and co-inventor of the OCMS technology
  • Responsible for the discovery of numerous critical antibodies, including the new international potency standard for inactivated poliovirus vaccines (IPV).

Rama Devudu Puligedda, PhD

Director of Immunology

Scientific Advisory Board

  • Diabetes, Obesity, and Metabolism KOL
  • Studies the molecular control of metabolism
  • Director of the Rodent Metabolic Phenotyping Core at Penn

Paul M. Titchenell, Ph.D.

Associate Professor, Physiology at Penn

  • RSV, Immunology and Infectious Diseases KOL
  • Clinical pediatric lead, oversees difficult-to-treat infections at U Hospital Southhampton
  • Director of the Southampton NIHR Clinical Research

Saul N. Faust, MBBS, FRCPCH, PhD, FHEA, OBE

Professor, Pediatric
Immunology & Infect at UHS

  • Independent Biopharma Strategy Consultant
  • SVP, Strategic Planning, Sudler & Hennessey
  • Various marketing positions at Bristol-Myers Squibb, Amgen, Merck

Daniela Matson

Targets & Indication